SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SRPT • US8036071004

19.73 USD
-0.55 (-2.71%)
At close: Feb 4, 2026
19.73 USD
0 (0%)
After Hours: 2/4/2026, 4:20:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SRPT. SRPT was compared to 524 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • SRPT had negative earnings in the past year.
  • SRPT had a negative operating cash flow in the past year.
  • SRPT had negative earnings in 4 of the past 5 years.
  • In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

  • With an excellent Return On Assets value of -7.77%, SRPT belongs to the best of the industry, outperforming 85.31% of the companies in the same industry.
  • The Return On Equity of SRPT (-20.57%) is better than 83.02% of its industry peers.
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • SRPT's Gross Margin of 76.25% is amongst the best of the industry. SRPT outperforms 84.16% of its industry peers.
  • In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

  • SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SRPT has been increased compared to 1 year ago.
  • Compared to 5 years ago, SRPT has more shares outstanding
  • SRPT has a better debt/assets ratio than last year.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • SRPT has an Altman-Z score of -0.05. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.05, SRPT is in the better half of the industry, outperforming 60.31% of the companies in the same industry.
  • SRPT has a Debt/Equity ratio of 0.78. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
  • SRPT has a worse Debt to Equity ratio (0.78) than 72.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z -0.05
ROIC/WACCN/A
WACC7.48%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

  • SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.95, SRPT is doing worse than 64.69% of the companies in the same industry.
  • A Quick Ratio of 1.79 indicates that SRPT should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.79, SRPT is not doing good in the industry: 76.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.79
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

  • The earnings per share for SRPT have decreased strongly by -197.60% in the last year.
  • Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 47.15%.
  • The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%

3.2 Future

  • SRPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.98% yearly.
  • Based on estimates for the next years, SRPT will show a decrease in Revenue. The Revenue will decrease by -5.08% on average per year.
EPS Next Y-338.34%
EPS Next 2Y6.65%
EPS Next 3Y-4.7%
EPS Next 5Y2.98%
Revenue Next Year14.04%
Revenue Next 2Y-7.99%
Revenue Next 3Y-7.23%
Revenue Next 5Y-5.08%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
  • SRPT is valuated cheaply with a Price/Forward Earnings ratio of 7.61.
  • SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 99.05% of the companies in the same industry.
  • SRPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.51.
Industry RankSector Rank
PE N/A
Fwd PE 7.61
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • A cheap valuation may be justified as SRPT's earnings are expected to decrease with -4.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.65%
EPS Next 3Y-4.7%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (2/4/2026, 4:20:02 PM)

After market: 19.73 0 (0%)

19.73

-0.55 (-2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-24
Inst Owners84.9%
Inst Owner Change0.11%
Ins Owners5.13%
Ins Owner Change19.39%
Market Cap2.07B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts67.27
Price Target30.27 (53.42%)
Short Float %21.3%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)0.41%
PT rev (3m)-8.28%
EPS NQ rev (1m)7.46%
EPS NQ rev (3m)-9.96%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)-22.02%
Revenue NQ rev (1m)2.64%
Revenue NQ rev (3m)10.84%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)4.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.61
P/S 0.86
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)2.59
Fwd EY13.14%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.77%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 290.01%
Cap/Sales 5.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.79
Altman-Z -0.05
F-Score3
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-338.34%
EPS Next 2Y6.65%
EPS Next 3Y-4.7%
EPS Next 5Y2.98%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year14.04%
Revenue Next 2Y-7.99%
Revenue Next 3Y-7.23%
Revenue Next 5Y-5.08%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-268.11%
EBIT Next 3Y7.84%
EBIT Next 5Y4.67%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRPT.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.


What is the profitability of SRPT stock?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.


How financially healthy is SAREPTA THERAPEUTICS INC?

The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 3 / 10.